The potential of computational psychiatry in the search for biological markers of depressive disorders

 

Authors

 

L.A. Levchuk

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesбTomsk, Russian Federation

S.A. Ivanova

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesбTomsk, Russian Federation

 

https://doi.org/10.26617/1810-3111-2026-3(132)-37-47

 

Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2026; 3 (132):  37-47.

 

Abstract

Background. Depressive disorders are socially significant diseases with a high prevalence across all age groups. Given the difficulties of early diagnosis, the negative consequences of misdiagnosis for treatment and recovery, the increased risk of suicidal behavior, increased cognitive and functional impairment, and the growing economic burden, the search for various biological markers of depressive disorders is of particular importance. Objective. To identify functional relationships between factors of neuroplasticity, neurodegeneration, and immunoinflammation and to determine potential biological markers of depressive disorders. Material and Methods. The construction and determination of protein-protein interactions were implemented using the STRING online service (https://string-db.org/), which includes publicly available databases on signaling, regulatory, and metabolic pathways. Results. A bioinformatics analysis of the biological pathways for the studied markers of neuroplasticity, immunoinflammation, and neurodegeneration revealed their integration into a unified regulatory network, identifying three clusters that interact via key proteins and support functional links between humoral factors of neuroplasticity, neurodegeneration, and immunoinflammation. Computational psychiatry, as an integrative discipline and a key component of translational medicine, offers prospects for improving diagnostic and prognostic approaches in psychiatry by characterizing the mechanisms of disorders at various levels and enabling the prediction of the most effective therapeutic strategies for each patient.

 

Keywords: depressive disorders, biomarkers, neuroplasticity, immunoinflammation, neurodegeneration, computational psychiatry.

 

Article (pdf)

 

Contacts

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Materials  

For citation: Levchuk L.A., Ivanova S.A. The potential of computational psychiatry in the search for biological markers of depressive disorders. Siberian Herald of Psychiatry and Addiction Psychiatry. 2026, 3 (132): 37-47. https://doi.org/10.26617/1810-3111-2026-3(132)-37-47.

 

REFERENCES

  1. Ivanets NN, Kinkul’kina MA, Tikhonova YuG. Depressive disorders of unipolar course: clinical picture, differentiated approaches to therapy. Moscow: RAS, 2020:230 (in Russian).
  2. Ivanova SA, Losenkov IS, Levchuk LA, Boiko AS, Vyalova NM, Simutkin GG, Bokhan NA. Depressive disorders: pathogenesis hypotheses and potential biological markers. Novosibirsk, Publishing House of the Siberian Branch of the Russian Academy of Sciences, 2018:199 (in Russian).
  3. Kaleda VG. Depression is the leading problem of clinical psychiatry. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11-2):7-8. https://doi.org/10.17116/jnevro20231231127(in Russian).
  4. Vasilieva SN, Simutkin GG, Schastnyy ED, Surovtseva AK, Ukraintsev II, Altynbekov KS. Combination of mood disorders and alcohol dependence: clinical significance of comorbidity, social adaptation of patients. Siberian Herald of Psychiatry and Addiction Psychiatry. 2022; 4 (117): 14-21. https://doi.org/10.26617/1810-3111-2022-4(117)-14-21 (in Russian).
  5. Krasnov VN. Depression: a large-scale problem and possibilities overcome it. Mental Health. 2023;18(8):68-69. https://doi.org/10.25557/2074-014X.2023.08.68-69 (in Russian).
  6. Kjaerstad HL, Nordseth BOB, Vinberg M, Kessing LV, Miskowiak KW. Characterizing high cognitive performance in persons with mood disorders and their unaffected relatives: associations with emotional cognition, functioning, and clinical outcomes. Int J Bipolar Disord. 2026 Mar 10;14(1):15. https://doi.org/10.1186/s40345-026-00417-x.
  7. Culpepper L, Martin A, Nabulsi N, Parikh M. The humanistic and economic burden associated with major depressive disorder: A retrospective cross-sectional analysis. Adv Ther. 2024 May;41(5):1860-1884. https://doi.org/10.1007/s12325-024-02817-w. Epub 2024 Mar 11. PMID: 38466558; PMCID: PMC11052813.
  8. Zhang Z, Chen X, Wu S, Chen X, Wang X, Liu C, Zeng N, Liu Y, Huo T, Liu X, Shi L, Yan W, Yuan K, Meng S, Wu P, Javed A, Alibudbud R, Shi J, Sun Y, Lu L, Bao Y. Global, regional and national burden of anxiety and depression disorders from 1990 to 2021, and forecasts up to 2040. J Affect Disord. 2026 Jan 15;393(Pt A):120299.https://doi.org/10.1016/j.jad.2025.120299. Epub 2025 Sep 9. PMID: 40935255..
  9. Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry. 2004;65 Suppl 4:5-10. PMID: 15046536.
  10. Pastis I, Santos MG, Paruchuri A. Exploring the role of inflammation in major depressive disorder: beyond the monoamine hypothesis. Front Behav Neurosci. 2024 Jan 17;17:1282242.https://doi.org/10.3389/fnbeh.2023.1282242. PMID: 38299049; PMCID: PMC10829100.
  11. Vetlugina TP, Nikitina VB, Lobacheva OA, Nevidimova TI. Fundamentals of Clinical Psychoneuroimmunology: A Textbook. Tomsk: Knigograd Publishing House, 2014:124 (in Russian).
  12. Dubinina EE, Shchedrina LV, Mazo GE. Basic biochemical aspects of the pathogenesis of depression. Part II. Advances in Physiological Sciences. 2021;52(1):31-48. https://doi.org/10.31857/S0301179821010033 (in Russian).
  13. Kasyanov ED, Mazo GE. The hypothalamic-pituitary-adrenal axis functioning in depressive disorder: current state of the problem. Mental Health. 2017;15;8(135):27-34 (in Russian).
  14. Klyushnik TP, Sarmanova ZV, Subbotskaya NV, Barkhatova AN. Systemic immune responses in endogenous depressions. Russian Journal of Psychiatry. 2015;(5):85-91. https://doi.org/http://dx.doi.org/10.24411/1560-957X-2015-1%25x (in Russian).
  15. Paderina DZ, Mikhalitskaya EV, Vyalova NM, Roshchina OV, Simutkin GG, Ivanova SA. Polymorphism of neurotrophin genes and aggressive behavior in patients with affective disorders. Siberian Herald of Psychiatry and Addiction Psychiatry. 2025;4(129):23-30. https://doi.org/10.26617/1810-3111-2025-4(129)-23-30 (in Russian).
  16. Tiganov AS, Kopeĭko GI, Brusov OS, Kliushnik TP. New findings in the study of the pathogenesis and treatment of endogenous depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(11):65‑72 (in Russian).
  17. Uzbekov MG, Shikhov SN, Kryukov VV, Krasnov VN. The influence of antidepressant therapy on the level of brain-derived neurotrophic factor in the blood serum of patients with melancholic depression: a pilot study. Siberian Herald of Psychiatry and Addiction Psychiatry. 2025; 2 (127): 5-14. https://doi.org/10.26617/18103111-2025-2(127)-5-14 (in Russian).
  18. Kouba BR, de Araujo Borba L, Borges de Souza P, Gil-Mohapel J, Rodrigues ALS. Role of inflammatory mechanisms in major depressive disorder: from etiology to potential pharmacological targets. Cells. 2024 Feb 28;13(5):423.https://doi.org/10.3390/cells13050423. PMID: 38474387; PMCID: PMC10931285.
  19. Loonen AJM, Ivanova SA. Circuits regulating pleasure and happiness - focus on potential biomarkers for circuitry including the habenuloid complex. Acta Neuropsychiatr. 2022 Oct;34(5):229-239. https://doi.org/10.1017/neu.2022.15.
  20. Mednova IA, Levchuk LA, Boiko AS, Roschina OV, Simutkin GG, Bokhan NA, Loonen AJM, Ivanova SA. Cytokine level in patients with mood disorder, alcohol use disorder and their comorbidity. World J Biol Psychiatry. 2023 Mar;24(3):243-253. https://doi.org/10.1080/15622975.2022.2095439.
  21. Ivanets NN, Kinkulkina MA, Tikhonova YuG, Avdeeva TI. The current state and future prospects of depression research (clinical and classification problems). S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(10):76-81.https://doi.org/10.17116/jnevro201811810176.
  22. Adams RA, Huys QJ, Roiser JP. Computational Psychiatry: towards a mathematically informed understanding of mental illness. J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):53-63. https://doi.org/10.1136/jnnp-2015-310737. Epub 2015 Jul 8. PMID: 26157034; PMCID: PMC4717449.
  23. Huys QJM, Browning M, Paulus MP, Frank MJ. Advances in the computational understanding of mental illness. Neuropsychopharmacology. 2021 Jan;46(1):3-19. https://doi.org/10.1038/s41386-020-0746-4. Epub 2020 Jul 3. PMID: 32620005; PMCID: PMC7688938.
  24. Paulus MP, Thompson WK. Computational approaches and machine learning for individual-level treatment predictions. Psychopharmacology (Berl). 2021 May;238(5):1231-1239.https://doi.org/10.1007/s00213-019-05282-4. Epub 2019 May 27. PMID: 31134293; PMCID: PMC6879811.
  25. Vasilchenko KF, Chumakov EM. Current status, challenges and future prospects in computational psychiatry: a narrative review. Consort Psychiatr. 2023;4(3):33-42. Published 2023 Sep 29. https://doi.org/10.17816/CP11244 (in Russian).
  26. Bernardini F, Attademo L, Cleary SD, Luther C, Shim RS, Quartesan R, Compton MT. Risk prediction models in psychiatry: Toward a new frontier for the prevention of mental illnesses. J Clin Psychiatry. 2017 May;78(5):572-583.https://doi.org/10.4088/JCP.15r10003.
  27. Schnack HG, Kahn RS. Detecting Neuroimaging Biomarkers for Psychiatric Disorders: Sample Size Matters. Front Psychiatry. 2016 Mar 31;7:50. https://doi.org/10.3389/fpsyt.2016.00050.
  28. Wager S, Athey S. Estimation and inference of heterogeneous treatment effects using random forests. J Am Stat Assoc. 2018;113(523):1228-1242. https://doi.org/10.1080/01621459.2017.1319839.
  29. Yip SW, Barch DM, Chase HW, Flagel S, Huys QJM, Konova AB, Montague R, Paulus M. From computation to clinic. Biol Psychiatry Glob Open Sci. 2022 Apr 2;3(3):319-328.https://doi.org/10.1016/j.bpsgos.2022.03.011. PMID: 37519475; PMCID: PMC10382698.
  30. Kendler KS. DSM disorders and their criteria: how should they inter-relate? Psychol Med. 2017 Sep;47(12): 2054-2060.https://doi.org/10.1017/S0033291717000678.
  31. Babu M, Snyder M. Multi-omics profiling for health. Mol Cell Proteomics. 2023 Jun;22(6):100561. https://doi.org/10.1016/j.mcpro.2023.100561. Epub 2023 Apr 27. PMID: 37119971; PMCID: PMC10220275.
  32. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001 Mar;69(3):89-95.https://doi.org/10.1067/mcp.2001.113989.
  33. Giacomini KM. Biomarkers come of age in clinical pharmacology. Clin Pharmacol Ther. 2023 May;113(5):945-947.https://doi.org/10.1002/cpt.2880. PMID: 37069736.
  34. Levchuk LA, Meeder EMG, Roschina OV, Loonen AJM, Boiko AS, Michalitskaya EV, Epimakhova EV, Losenkov IS, Simutkin GG, Bokhan NA, Schellekens AFA, Ivanova SA. Exploring brain derived neurotrophic factor and cell adhesion molecules as biomarkers for the transdiagnostic symptom anhedonia in alcohol use disorder and comorbid depression. Front Psychiatry. 2020;11:296. Published 2020 Apr 20.https://doi.org/10.3389/fpsyt.2020.00296.
  35. Levchuk LA, Roshchina OV, Simutkin GG, Bokhan NA, Ivanova SA. Peripheral markers of nervous tissue damage in addictive and affective disorders. Neurochemical Journal. 2021;38(1):77-82. https://doi.org/10.1134/S1819712421010074 (in Russian).
  36. Levchuk LA, Roschina OV, Mikhalitskaya EV, Epimakhova EV, Simutkin GG, Bokhan NA, Ivanova SA. Serum levels of S100B protein and myelin basic protein as potential biomarkers of recurrent depressive disorders. J Pers Med. 2023 Sep 21;13(9):1423. https://doi.org/10.3390/jpm13091423. PMID: 37763190; PMCID: PMC10532562.